<?xml version="1.0" encoding="UTF-8"?>
<p>In almost all of the previous clinical studies of IVIg in patients with CIDP, only one dose of IVIg was assessed.
 <xref rid="jns12267-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="jns12267-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="jns12267-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="jns12267-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="jns12267-bib-0007" ref-type="ref">7</xref>, 
 <xref rid="jns12267-bib-0008" ref-type="ref">8</xref>, 
 <xref rid="jns12267-bib-0009" ref-type="ref">9</xref>, 
 <xref rid="jns12267-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="jns12267-bib-0011" ref-type="ref">11</xref> The efficacy and safety of different induction doses of IVIg (0.05, 0.2, or 0.4 g/kg/d for 5 days) has been evaluated head‐to‐head in only one non‐placebo‐controlled study of Japanese patients with CIDP (
 <italic>n</italic> = 40) or multi‐focal motor neuropathy (
 <italic>n</italic> = 20), in which dose‐dependent improvements in electrophysiology and clinical disease at 5 weeks were observed in all patients.
 <xref rid="jns12267-bib-0012" ref-type="ref">12</xref> The Polyneuropathy and Treatment with Hizentra (PATH) study, which investigated 2 different maintenance doses of weekly subcutaneous immunoglobulin (SCIg) 0.2 or 0.4 g/kg in 172 patients with CIDP, showed that both doses of SCIg had significantly superior efficacy to placebo.
 <xref rid="jns12267-bib-0013" ref-type="ref">13</xref>, 
 <xref rid="jns12267-bib-0014" ref-type="ref">14</xref>
</p>
